Внутрипузырная химиотерапия больных поверхностным раком мочевого пузыря: возможности повышения эффективности и перспективы

1. Kaasinen E., Wijkström H., Malmström P.-U. et al. Alternating Mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol 2003; 43: 637–45.

2. Herr H. The value of second transurethral resection in evaluating patients with bladder tumors. Urology 1999; 162: 74–6.

3. Klan R., Loy V., Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. Urology 1991; 146: 316–8.

4. Oosterlinck W., Lobel B., Jakse G. et al. Guidelines on bladder cancer. Eur Urol 2002; 41(2): 105–12.

5. Матвеев Б.П. Химиотерапия поверхностного рака мочевого пузыря. В кн. Клиническая онкоурология. Под ред. проф. Б.П.Матвеева. М., 2003; с. 260–70.

6. Sylvester R., Van der Meijden A., Witjes J.A., Kurth K. Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of carcinoma in situ: a metaanalysis of the published results of randomized clinical trials. Eur Urol Suppl 2005; 4(3): 219.

7. Lamm D.L. Diagnosis and treatment of bladder cancer. Anti-Cancer Drugs 1992; 3(1): 39–47.

8. Kurth K., Tunn U., Ay R. et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European organization for research and treatment of cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 1997; 158(2): 378–84.

9. Pawinski A., Bouffioux C., Sylvester R. et al. Meta-analysis of EORTC/MRC random mixed clinical trials for prophylactic treatment of Ta, T1 bladder cancer. J Urol 1996; 155: 492A.

10. Tolley D.A., Parmar M.K.B., Grigor K.M., Lallemand G. and the Medical research council superficial bladder cancer working party. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol 1996; 155(4): 1233–8.

11. Solsona Е., Iborra I., Ricos J.V. et al. Effectiveness of a single immediate Mitomycin C instillation in patients with low risk superficial bladder cancer: short and long term followup. J Urol 1999; 161(4): 1120–3.

12. European Association of Urology. Guidelines. 2006; р. 1–17.

13. Koga H., Kuroiwa K., Yamagushi A. et al. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 2004; 171(1): 153–7.

14. Sekine H., Fukui I., Yamada T. et al. Intravesical Mitomycin C and Doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. J Urol 1994; 151(1): 27–30.

15. Юрченко А.Н., Сафиуллин К.Н., Карякин О.Б. Лечение поверхностного рака мочевого пузыря у больных с неблагоприятным прогнозом. Онкоурология 2005; (2): 46–50.

16. Ali-El-Dein B., Nabeen A., Ismail E-H., Ghoneim M. Sequential bacillus CalmetteGuerin and epirubicin versus bacillus CalmetteGuerin alone for superficial bladder tumors: a randomized prospective study. J Urol 1999; 162(2): 339–42.

17. Rintala E., Jauhiainen K., Kaasinen E. et al. Alternating Mitomycin C and Bacillus CalmetteGuerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol 1996; 156(1): 56–60.

18. Wijkström H., Kaasinen E., Malmström P.-U. et al. A Nordic study comparing intravesical instillations of alternating Mitomycin C and BCG with BCG alone in carcinoma in situ of the urinary bladder. J Urol 1999; 161(4): 286.

19. Witjes J.A., Caris C.T.M., Mungan N.A. et al. Results of a randomized phase III trial of sequential intravesical therapy with Mitomycin C and Bacillus Calmette-Guerin versus Mitomycin C alone in patients with superficial bladder cancer. J Urol 1998; 160(5): 1668–72.

20. Koga H., Hasui Y., Fujimoto N. et al. A randomized controlled trial of prophylactic intravesical instillation chemotherapy in combination with the oral administration of a Lactobacillus Casei preparation versus intravesical instillation chemotherapy alone for recurrence after a transurethral resection of superficial bladder cancer. J Urol 2005; 173(4): 249.

21. Ungelmann U., Knopf H.J., Graff J. еt al. Interferon-α2b instillation prophylaxis in superficial bladder cancer – a prospective, controlled three-armed trial. Anti-Cancer Drugs 1992; 3 (Suppl 1): 33–7.

22. Torelli F., Catanzaro F. (Desio), Conti G. et al. High-dose Epirubicin in prophylactic treatment of T1G2 superficial bladder tumors. Eur Urol 2001; 39 (1 Suppl 2): 11–4.

23. Mitsumori K., Tsuchiya N., Habuchi T. et al. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection. BJU Int 2004; 94: 317–21.

24. Kuroda M., Niijima T., Kotake T. et al. Effect of prophylactic treatment with intravesical Epirubicin on recurrence of superficial bladder cancer – the 6th trial of the Japanese Urological Cancer Research Group (JUCRC): a randomized trial of intravesical Epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40ml. Eur Urol 2004; 45: 600–5.

25. Au J L.-S., Badalament R.A., Wientjes G. et al. Methods to improve efficacy of intravesical Mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001; 93(8): 597–604.

26. Van der Heijden A.G., Kiemeney L.A., Gofrit O.N. et al. Preliminary European results of local Microwave Hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004; 46(1): 65–72.

27. Paroni R., Salonia A., Lev A. et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Clin Pharmacol 2001; 52: 273–8.

28. Malmström P.-U. Intravesical therapy of superficial bladder cancer. Clin Rev Oncol Hematol 2003; 47: 109–26.

29. Harris N.M., Duffy P.M., Crook T.J. et al. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. BJU Int 2002; 90: 957–64.

30. Di Stasi S.M., Giannantoni A., Massoud R. et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentrationdepth profiles studies. Cancer Res 1999;. 59: 4912.

31. Riedl C.R., Knoll M., Plas E., Pfluger H. Intravesical electromotive drug administration technique: preliminary results and side effects. J Urol 1998; 159: 1851–6.

32. Di Stasi S.M., Giannantoni A., Stephen R.L. et al. Intravesical electromotive Mitomycin C versus passive transport Mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 2003; 170: 777–82.

33. Ролевич А.И., Суконко О.Г., Красный С.А., Жуковец А.Г. Внутрипузырный электрофорез доксорубицина при поверхностном раке мочевого пузыря. Результаты проспективного рандомизированного исследования. Онкоурология 2005;(2): 34–40.

34. De Berardinis E., Antonini G., Peters G.J. et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 2004; 93(4) 491–4.

35. Palou J., Carca S. A., Segarra J. et al. Phase I pharmacokinetic study of a single intravesical instillation of Gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol 2004; 172: 485–8.

36. Laufer M., Ramalingam S., Schoenberg M.P. et al. Intravesical Gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003; 21(4): 697–703.

37. Witjes J.A., van der Heijden A.G., Vriesema J.L.J. et al. Intravesical Gemcitabine: a phase I and pharmacokinetic study. Eur Urol 2004; 45:182—6.

38. Bartoletti R., Cai T., Gacci M. et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology 2005; 66(4): 726–31.

39. Gontero P., Casetta G., Maso G. et al. Phase II study to investigate the ablative efficacy of intravesical administration of Gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 2004; 46: 339–43.

40. Calais da Silva F.M., Calais da Silva F.E. Phase 2 study 2000 mg of intravesical gemcitabine in marker lesions. Eur Urol Suppl 2005; 4(3): 222.

41. Серегин И.В., Самойленко В.М., Фигурин К.М. Внутрипузырное применение гемцитабина у больных поверхностным раком мочевого пузыря, резистентным к внутрипузырной иммунотерапии вакциной БЦЖ. Онкоурология 2005; (2): 32–4.

42. Büttner M., Strohmaier W.I., Heidecke H. Testing of chemosensitivity in patients with transitional cancer of the bladder. Eur Urol Suppl 2006; 5(2): 187.

43. McKiernan J.M., Murphy A.M., Goetzl M. et al. Phase I trial of intravesical docetaxel in the treatment of superficial bladder cancer resistant to standard intravesical therapy. J Urol 2005; 173(4): 247.

44. Van der Heijden A.G., Moonen P.M.J., Cornel E.B. et al. Phase II marker lesion study with intravesical instillation of EOquin™ in superficial bladder cancer, toxicity and marker response – the final results. Eur Urol Suppl 2006; 5(2): 188.